Clouds Darken Over Gilead's Zydelig In Europe Amid EMA Review
This article was originally published in Scrip
A fresh obstacle to Gilead Sciences Inc.'s blood cancer therapy Zydelig (idelalisib) is looming amid news the European Medicines Agency is reviewing the PI3K inhibitor's safety profile after a jump in serious adverse events, including deaths, mostly due to infections, observed in three clinical studies.
You may also be interested in...
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.